

Financial news for ACHN dated on 2020-01-28: The Daily Biotech Pulse: Acceleron's Positive Data Readout, Surface Oncology Gets Nod For Pushing 2 Antibodies Into Clinics

Financial news for ACHN dated on 2020-01-28: 71 Biggest Movers From Yesterday

Financial news for ACHN dated on 2020-01-27: 40 Stocks Moving In Monday's Mid-Day Session

Financial news for ACHN dated on 2020-01-27: Stocks That Hit 52-Week Highs On Monday

Financial news for ACHN dated on 2020-01-27: Achillion shares are trading higher after the company disclosed the FTC granted early termination of the waiting period for its pending acquisition by Alexion Pharmaceuticals.

Financial news for ACHN dated on 2020-01-27: 20 Healthcare Stocks Moving In Monday's Pre-Market Session

Financial news for ACHN dated on 2020-01-27: 14 Biotechnology Stocks Moving In Monday's Pre-Market Session

Financial news for ACHN dated on 2020-01-27: 22 Stocks Moving in Monday's Pre-Market Session

Financial news for ACHN dated on 2019-12-19: Achillion Shareholders Approve Agreement To Be Acquired By Alexion

Financial news for ACHN dated on 2019-12-09: Achillion Reports Data From Phase 2 Study Of Danicopan In Combo with Eculizumab In Paroxysmal Nocturnal Hemoglobinuria Patients Who Have Inadequate Response To Monotherapy At ASH

Financial news for ACHN dated on 2019-12-07: The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling

Financial news for ACHN dated on 2019-11-19: Achillion Pharmaceuticals Option Alert: Mar 20 \$7 Calls at the Ask: 5000 @ \$0.051 vs 32023 OI; Ref=\$6.295

Financial news for ACHN dated on 2019-11-19: Achillion Pharmaceuticals Announces European Medicines Agency Has Granted PRIME Designation To Co.'s Danicopan

Financial news for ACHN dated on 2019-11-11: Achillion Announces FDA Clearance of Investigational New Drug Application for ACH-5228

Financial news for ACHN dated on 2019-11-07: Achillion Pharmaceuticals Earlier Reported Q3 EPS \$(0.14) Down From \$(0.12) YoY

Financial news for ACHN dated on 2019-11-01: Stocks That Hit 52-Week Highs On Friday

Financial news for ACHN dated on 2019-10-21: 3 Stocks Moving On FDA Verdicts: Alexion, AstraZeneca, Foamix

Financial news for ACHN dated on 2019-10-18: Benzinga's Top Upgrades, Downgrades For October 18, 2019

Financial news for ACHN dated on 2019-10-18: SVB Leerink Downgrades Achillion Pharmaceuticals to Market Perform, Raises Price Target to \$6.3

Financial news for ACHN dated on 2019-10-17: Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Thursday, October 17, 2019

Financial news for ACHN dated on 2019-10-17: The Daily Biotech Pulse: FDA Panel Backs Shionogi's Antibiotic, Hepion Surges On Data Publication, Innate Pharma IPO

Financial news for ACHN dated on 2019-10-17: 54 Biggest Movers From Yesterday

Financial news for ACHN dated on 2019-10-16: Mid-Afternoon Market Update: Crude Oil Up 1%; Tech Data Shares Spike Higher

Financial news for ACHN dated on 2019-10-16: 44 Stocks Moving In Wednesday's Mid-Day Session

Financial news for ACHN dated on 2019-10-16: Mid-Day Market Update: Achillion Pharmaceuticals Jumps Following Acquisition News; Natera Shares Plunge

Financial news for ACHN dated on 2019-10-16: Stocks That Hit 52-Week Highs On Wednesday

Financial news for ACHN dated on 2019-10-16: Mid-Morning Market Update: Markets Edge Lower; Bank of America Earnings Beat Expectations

Financial news for ACHN dated on 2019-10-16: Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Wednesday, October 16, 2019

Financial news for ACHN dated on 2019-10-16: 17 Healthcare Stocks Moving In Wednesday's Pre-Market Session

Financial news for ACHN dated on 2019-10-16: 23 Stocks Moving in Wednesday's Pre-Market Session

Financial news for ACHN dated on 2019-10-16: Alexion To Acquire Achillion Pharma For \$930M

Financial news for ACHN dated on 2019-10-16: Achillion Pharmaceuticals shares are trading higher after Alexion Pharma announced it will acquire the company for \$6.30 per share in cash plus added contingent considerations for a total potential value of \$8.30 per share.

Financial news for ACHN dated on 2019-10-16: Alexion Pharma Reports Purchase Of Achillion Pharma For Initial Value Of \$6.30/Share In Cash Plus Added Contingent Considerations For Total Potential Value Of \$8.30/Share

Financial news for ACHN dated on 2019-09-27: 21 Healthcare Stocks Moving In Friday's Pre-Market Session

Financial news for ACHN dated on 2019-09-26: A Look At Benzinga Pro's Most-Searched Tickers For September 26, 2019

Financial news for ACHN dated on 2019-09-26: Shares of several healthcare companies are trading lower, potentially on recent Democratic primary polls showing Senator Elizabeth Warren in the lead.

Financial news for ACHN dated on 2019-09-26: Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Thursday, September 26, 2019

Financial news for ACHN dated on 2019-09-25: 34 Stocks Moving In Wednesday's Mid-Day Session

Financial news for ACHN dated on 2019-09-25: 23 Healthcare Stocks Moving In Wednesday's Pre-Market Session

Financial news for ACHN dated on 2019-09-25: 24 Stocks Moving in Wednesday's Pre-Market Session

Financial news for ACHN dated on 2019-09-25: Achillion Pharmaceuticals shares are trading higher after announced that the FDA has granted Breakthrough Therapy designation for danicopan for patients with paroxysmal nocturnal hemoglobinuria.

Financial news for ACHN dated on 2019-09-25: Achillion Receives Breakthrough Therapy Designation From FDA For Danicopan For Treatment Of Paroxysmal Nocturnal Hemoglobinuria

Financial news for ACHN dated on 2019-09-24: Shares of many pharma/therapeutics stocks trading lower in sympathy with overall market weakness. Reports China is planning to cut prices for widely-used drugs may also be pressuring the sector today.

Financial news for ACHN dated on 2019-08-14: Top 10 Most Overbought Stocks Via Benzinga Pro's Screener Tool For Wed., August 14, 2019

Financial news for ACHN dated on 2019-08-08: Achillion Pharmaceuticals Earlier Reported Ach-5228'S Near Complete And Sustained Inhibition Of The Alternative Pathway And Its Tolerability Support Us Ind Submission Q4 2019

Financial news for ACHN dated on 2019-08-08: Achillion Pharmaceuticals Earlier Reported Danicopan (Ach-4471) Phase 2 Combination Therapy Interim Data Showed Clinically Meaningful Improvements In Laboratory Parameters Of Pnh; End-Of-Phase 2 Meeting Activities Initiated With FDA

Financial news for ACHN dated on 2019-08-08: Achillion Pharmaceuticals Earlier Reported Q2 EPS \$(0.14), Inline

Financial news for ACHN dated on 2019-07-30: 33 Healthcare Stocks Moving In Today's Pre-Market Session

Financial news for ACHN dated on 2019-07-30: 42 Stocks Moving In Tuesday's Pre-Market Session

Financial news for ACHN dated on 2019-07-30: 45 Healthcare Stocks Moving In Monday's After-Market Session

Financial news for ACHN dated on 2019-07-29: 35 Stocks Moving In Monday's Pre-Market Session

Financial news for ACHN dated on 2019-07-29: 62 Biggest Movers From Friday

Financial news for ACHN dated on 2019-07-26: Companies That Achieved 52-Week Highs Friday

Financial news for ACHN dated on 2019-07-26: 45 Stocks Moving In Friday's Mid-Day Session

Financial news for ACHN dated on 2019-07-26: Achillion Pharma shares trading higher on no company-specific news. Shares have doubled in the last week and have broken, breaking above an important technical level at \$3.50. The stock crossed technical levels at \$4 and \$4.50 today.

Financial news for ACHN dated on 2019-07-24: 24 Stocks Moving In Wednesday's Pre-Market Session

Financial news for ACHN dated on 2019-07-24: 60 Biggest Movers From Yesterday

Financial news for ACHN dated on 2019-07-23: 45 Stocks Moving In Tuesday's Mid-Day Session

Financial news for ACHN dated on 2019-07-23: 58 Biggest Movers From Yesterday

Financial news for ACHN dated on 2019-07-22: 35 Stocks Moving In Monday's Pre-Market Session

Financial news for ACHN dated on 2019-07-22: Achillion Pharmaceuticals shares are trading higher after the company reported ACH-5228 delivered 'near complete and sustained inhibition' of the complement alternative pathway in its Phase 1 trial.

Financial news for ACHN dated on 2019-07-22: Achillion Announces Results From Study Of ACH-5228

Financial news for ACHN dated on 2019-05-17: The Daily Biotech Pulse: Axovant Doses First Patient In Gene Therapy Trial, Agile Resubmits NDA, ADMA Prices Offering

Financial news for ACHN dated on 2019-05-17: Achillion Reports Interim Data For ACH-4471 Phase 2 Combination Trial with Eculizumab at The New Era of Aplastic Anemia and PNH Meeting: Increased Hemoglobin, Nearly Eliminated Need For Transfusions In Patients

Financial news for ACHN dated on 2019-05-14: Achillion Granted Twentieth Patent for Factor D Portfolio

Financial news for ACHN dated on 2019-05-11: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs

Financial news for ACHN dated on 2019-05-09: Achillion Pharmaceuticals Q1 EPS \$(0.14), Inline

Financial news for ACHN dated on 2019-05-03: 10 Biggest Price Target Changes For Friday

Financial news for ACHN dated on 2019-05-03: Benzinga's Top Upgrades, Downgrades For May 3, 2019

Financial news for ACHN dated on 2019-05-03: Barclays Downgrades Achillion Pharmaceuticals, Inc. - Common Stock to Underweight, Lowers Price Target to \$2.5

Financial news for ACHN dated on 2019-04-18: Shares of several drug companies are trading lower amid continued efforts from Washington to curb prescription drug prices. The overall healthcare sector has seen weakness recently due to uncertainty over the future of healthcare policy.

Financial news for ACHN dated on 2019-04-17: Shares of several drug companies are trading lower amid continued efforts from Washington to curb prescription drug prices. The overall healthcare sector has seen weakness recently due to uncertainty over the future of healthcare policy.

Financial news for ACHN dated on 2019-04-04: 55 Biggest Movers From Yesterday

Financial news for ACHN dated on 2019-04-03: 40 Stocks Moving In Wednesday's Mid-Day Session

Financial news for ACHN dated on 2019-04-03: Mid-Day Market Update: NASDAQ Up Over

1%; Obalon Therapeutics Shares Plummet

Financial news for ACHN dated on 2019-04-03: Achillion Pharmaceuticals shares are trading higher after the company announced achievement of an enrollment milestone in its phase 2 trials for C3 Glomerulopathy; the company enrolled 23 patients.

Financial news for ACHN dated on 2019-04-03: Achillion Pharmaceuticals Enrolled 23 Patients In Ach-4471 Phase 2 C3g Six And 12-month Clinical Trials

Financial news for ACHN dated on 2019-03-27: Achillion Reports Completion Of Enrollment In Phase 2 PNH Combo Trial

Financial news for ACHN dated on 2019-03-07: Achillion Pharmaceuticals Q4 EPS \$(0.12) Beats \$(0.15) Estimate

Financial news for ACHN dated on 2019-02-11: Achillion Pharma Announces Brian Di Donato CFO

Financial news for ACHN dated on 2019-01-31: UPDATE: Achillion Says Is Planning Investigational New Drug Submission In Q4'19

Financial news for ACHN dated on 2019-01-31: Achillion Announces First Dosing in Phase 1 Multiple Ascending Dose Study of ACH-5228 Next-Generation Oral Factor D Inhibitor in Healthy Volunteers

Financial news for ACHN dated on 2019-01-03: The Daily Biotech Pulse: Aevi's ADHD Drug Flunks Mid-Stage Trial, Bristol-Myers To Buy Celgene, Teva Settles With Amgen

Financial news for ACHN dated on 2018-12-21: The Daily Biotech Pulse: Proteostasis Delays Data, Akron Gets New CEO, Pfizer Halts Vaccine Trial

Financial news for ACHN dated on 2018-12-20: Stocks Which Set New 52-Week Low Yesterday, Tues., Dec. 20, 2018

Financial news for ACHN dated on 2018-12-20: The Daily Biotech Pulse: Tilray Inks Cannabis Drink Pact, Double Delight For Merck, FDA Snub For Spectrum

Financial news for ACHN dated on 2018-12-19: Stocks Which Set New 52-Week Low Yesterday, Tues., Dec. 18, 2018

Financial news for ACHN dated on 2018-12-19: The Daily Biotech Pulse: Pfizer-Glaxo Set Up Consumer Health Care Venture, New Patent For Adamas

Financial news for ACHN dated on 2018-12-19: 45 Biggest Movers From Yesterday

Financial news for ACHN dated on 2018-12-18: 38 Stocks Moving In Tuesday's Mid-Day Session

Financial news for ACHN dated on 2018-12-18: Benzinga Pro's Top 10 Most-Searches Tickers For Morning Of Tues., Dec. 18, 2018

Financial news for ACHN dated on 2018-12-18: 25 Stocks Moving In Tuesday's Pre-Market Session

Financial news for ACHN dated on 2018-12-18: The Daily Biotech Pulse: Puma Aces Late-Stage Trial, Chinese Cheer For FibroGen, J&J \$5B Buyback Plan

Financial news for ACHN dated on 2018-12-18: 50 Biggest Movers From Yesterday

Financial news for ACHN dated on 2018-12-17: 4 Stocks Moving In Monday's After-Hours Session

Financial news for ACHN dated on 2018-12-17: Achillion Reports Interim Data For ACH-4471 Phase 2 Trials And Provides Clinical Development Strategy Update; Co. Expects 2019 Cash Burn \$80M-\$85M, Expects Year-End 2018 Cash And Marketable Securities Balance Of ~\$270M

Financial news for ACHN dated on 2018-12-17: 40 Stocks Moving In Monday's Mid-Day Session

Financial news for ACHN dated on 2018-12-16: The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials

Financial news for ACHN dated on 2018-12-10: Achillion Announces Interim Clinical Trial Data and Strategic Update Planned for Dec 17th, 2018

Financial news for ACHN dated on 2018-11-07: Achillion Pharmaceuticals Q3 EPS \$(0.12) Beats \$(0.14) Estimate

Financial news for ACHN dated on 2018-09-10: Achillion Announces Paul Firuta COO

Financial news for ACHN dated on 2018-08-30: 45 Biggest Movers From Yesterday

Financial news for ACHN dated on 2018-08-23: 50 Biggest Movers From Yesterday

Financial news for ACHN dated on 2018-08-08: Achillion Pharmaceuticals Q2 EPS \$(0.12) Beats \$(0.13) Estimate

Financial news for ACHN dated on 2018-08-07: Stocks Which Set New 52-Week Low Yesterday, August 6th

Financial news for ACHN dated on 2018-08-06: Stocks Which Set New 52-Week Lows Friday, August 3rd

Financial news for ACHN dated on 2018-08-01: Stocks Which Set New 52-Week Low Yesterday, July 31

Financial news for ACHN dated on 2018-08-01: Benzinga's Biotech Pulse: Pfizer's Xeljanz Gets EU Nod, NewLink Losses Narrow, Neuralstem Commences Stroke Drug Trial

Financial news for ACHN dated on 2018-07-10: Achillion Initiates Phase I First-In-Human Study of ACH-5548, A Third Oral Small Molecule Inhibitor Of Complement Factor D

Financial news for ACHN dated on 2018-05-21: SMid-Cap Biotech: Barclays Downgrades Prothena, Upgrades Achillion

Financial news for ACHN dated on 2018-05-21: Benzinga's Top Upgrades, Downgrades For May 21, 2018

Financial news for ACHN dated on 2018-05-21: 23 Stocks Moving In Monday's Pre-Market Session

Financial news for ACHN dated on 2018-05-21: Barclays Upgrades Achillion Pharmaceuticals to Equal-Weight

Financial news for ACHN dated on 2018-05-21: The Week Ahead In Biotech: PDUFA Dates, IPOs And More

Financial news for ACHN dated on 2018-05-02: Achillion Pharmaceuticals Reports Q1 2018 EPS of \$(0.15) vs \$(0.14) Est

Financial news for ACHN dated on 2018-02-27: 38 Biggest Movers From Yesterday

Financial news for ACHN dated on 2018-02-26: Achillion Pharmaceuticals Shares Up 15.7% As Co.'s ACH-4471 Received Positive Opinion for Orphan Drug Designation in the European Union

Financial news for ACHN dated on 2018-02-26: Mid-Afternoon Market Update: Telaria Falls Following Q4 Results; Achillion Pharmaceuticals Shares Surge

Financial news for ACHN dated on 2018-02-26: 28 Stocks Moving In Monday's Mid-Day Session

Financial news for ACHN dated on 2018-02-26: Benzinga Pro's 4 Stocks To Watch Today

Financial news for ACHN dated on 2018-02-26: 25 Stocks Moving In Monday's Pre-Market Session

Financial news for ACHN dated on 2018-02-26: Achillion Announces ACH-4471 Receives Positive Opinion for Orphan Drug Designation in the European Union for the Treatment of C3 Glomerulopathy

Financial news for ACHN dated on 2018-02-22: Achillion Promotes Joseph Truitt To Pres, COO

Financial news for ACHN dated on 2018-02-22: UPDATE: Achillion Sees Delivering ~\$10M Of YoY Savings During FY18; Will Impact ~20% Of Co.'s Workforce, Or ~70 Employees

Financial news for ACHN dated on 2018-02-22: Achillion Unveils Operational Restructuring Plan Aimed At Focusing Co.'s 'existing clinical and late-stage preclinical factor D inhibitors and reduce expenses to maintain its strong balance sheet'

Financial news for ACHN dated on 2018-02-22: Achillion Reports Q4 EPS \$(0.17) vs \$(0.16) Est.

Financial news for ACHN dated on 2018-02-08: Benzinga's Top Upgrades, Downgrades For February 8, 2018

Financial news for ACHN dated on 2018-02-08: B. Riley Initiates Coverage On Achillion Pharmaceuticals with Neutral Rating, Announces \$3.50 Price Target

Financial news for ACHN dated on 2017-12-20: Achillion Initiates Phase I First-In Study of ACH-5228, a Next-Generation Oral Small Molecule Inhibitor of Complement Factor D

Financial news for ACHN dated on 2017-12-18: 31 Stocks Moving In Monday's Pre-Market Session

Financial news for ACHN dated on 2017-12-18: A Peek Into The Markets: U.S. Stock Futures Signal Higher Start On Wall Street

Financial news for ACHN dated on 2017-12-18: Achillion Announces the Initiation of a Bioavailability Study of ACH-4471

Financial news for ACHN dated on 2017-12-18: Achillion Pharma is Granted Orphan Drug Designation for the Treatment to fC3 Glomerulopathy by the FDA

Financial news for ACHN dated on 2017-12-15: Achillion Shares Fall Following 700K Share Block Trade

Financial news for ACHN dated on 2017-11-17: 42 Biggest Movers From Yesterday

Financial news for ACHN dated on 2017-11-16: 38 Stocks Moving In Thursday's Mid-Day Session

Financial news for ACHN dated on 2017-11-16: 40 Stocks Moving In Thursday's Pre-Market Session

Financial news for ACHN dated on 2017-11-16: Achillion Pharma Shares Up 4+% Premarket Thurs. Following Late Wed. Announcement Offering Of 18.367M Common Shares Via JJDC Was Priced At \$2.75/Share

Financial news for ACHN dated on 2017-11-16: 40 Biggest Movers From Yesterday

Financial news for ACHN dated on 2017-11-15: 33 Stocks Moving In Wednesday's Mid-Day Session

Financial news for ACHN dated on 2017-11-15: A Peek Into The Markets: U.S. Stock Futures Tumble Ahead Of Economic Reports

Financial news for ACHN dated on 2017-11-15: 8 Stocks To Watch For November 15, 2017

Financial news for ACHN dated on 2017-11-14: Achillion Announces Secondary Offering Of 18.4M Shares

Financial news for ACHN dated on 2017-11-14: Achillion Reports Preliminary Proof-of-Concept With ACH-4471 for the Treatment of C3G

Financial news for ACHN dated on 2017-11-14: 14 Stocks Moving In Tuesday's After-Hours Session

Financial news for ACHN dated on 2017-11-06: Achillion Reports ACH-4471 Granted Orphan Drug Designation By FDA, Positive Opinion For Orphan Drug Designation In EU For Treatment Of Paroxysmal Nocturnal Hemoglobinuria

Financial news for ACHN dated on 2017-11-06: Achillion Reports ACH-4471 Granted Orphan Drug Designation by the FDA and Positive Opinion for Orphan Drug Designation in the European Union

Financial news for ACHN dated on 2017-11-01: Achillion Reports Q3 EPS \$(0.14) vs. \$(0.18) Est.

Financial news for ACHN dated on 2017-10-27: 32 Stocks Moving In Friday's Pre-Market Session

Financial news for ACHN dated on 2017-10-24: USPTO Grants Composition of Matter Patent to Achillion for ACH-4471, First-in-Class Small Molecule Complement Alternative Pathway Factor D Inhibitor

Financial news for ACHN dated on 2017-09-28: 13G From RTW Investments On Achillion Pharma Shows 5.2% Stake

Financial news for ACHN dated on 2017-09-27: Achillion Pharma Shares Up 7% Wed., At Highest Level Since Major Earnings-Related Sell Off On Sept. 8; Stock Up 19% Since Sept. 14 Lows; Not Seeing Any News To Justify Price Action Wed., But Price Notably Held Above \$4 Support Level

Financial news for ACHN dated on 2017-09-11: Mid-Afternoon Market Update: Crude Oil Up Over 1%; Alamos Gold Shares Slide

Financial news for ACHN dated on 2017-09-11: 12 Biggest Mid-Day Losers For Monday

Financial news for ACHN dated on 2017-09-11: Mid-Day Market Update: Dow Up 1%; Achillion Pharmaceuticals Shares Plunge

Financial news for ACHN dated on 2017-09-11: Mid-Morning Market Update: Markets Open Higher; Teva Pharmaceutical Names Kaare Schultz As CEO

Financial news for ACHN dated on 2017-09-11: 18 Stocks Moving In Monday's Pre-Market Session

Financial news for ACHN dated on 2017-09-11: Janssen Terminates Worldwide Collaboration for Hepatitis C With Achillion Pharmaceuticals

Financial news for ACHN dated on 2017-09-11: Achillion Names Joseph Truitt as COO

Financial news for ACHN dated on 2017-08-10: Benzinga's Top Upgrades, Downgrades For August 10, 2017

Financial news for ACHN dated on 2017-08-10: Baird Downgrades Achillion Pharmaceuticals to Neutral

Financial news for ACHN dated on 2017-08-09: 20 Biggest Mid-Day Gainers For Wednesday

Financial news for ACHN dated on 2017-08-09: Mid-Day Market Update: Supreme Industries Climbs On Acquisition News; Fossil Group Shares Plunge

Financial news for ACHN dated on 2017-08-09: Mid-Morning Market Update: Markets Open Lower; Disney Earnings Beat Views

Financial news for ACHN dated on 2017-08-09: 18 Stocks Moving In Wednesday's Pre-Market Session

Financial news for ACHN dated on 2017-08-08: Achillion Reports Q2 EPS \$(0.16), Inline

Financial news for ACHN dated on 2017-07-10: Achillion Pharmaceuticals Announces Joel Barrish Resigning As Executive Vice President and Chief Scientific Officer

Financial news for ACHN dated on 2017-07-10: Achillion Pharmaceuticals Announces Mingjun Huang Promoted To Senior Vice President and Head of Research

Financial news for ACHN dated on 2017-06-30: Clinical Data Expected Today From Achillion Pharma, CytRX, and Valeant Pharma

Financial news for ACHN dated on 2017-06-05: Mid-Day Market Update: Crude Oil Down 1%; Forestar Shares Spike Higher

Financial news for ACHN dated on 2017-05-23: Companies Holding Annual Meetings Today Include Waste Connections, Eastman Kodak, Alarm.com, Amyris, Achillion Pharma, GNC, Amazon, Nokia, Merck, Nvidia, Pinnacle Foods, Wendy's, & Xerox

Financial news for ACHN dated on 2017-05-19: Mid-Day Market Update: Crude Oil Up 2%; Halozyme Therapeutics Shares Plunge

Financial news for ACHN dated on 2017-05-18: 15 Biggest Mid-Day Gainers For Thursday

Financial news for ACHN dated on 2017-05-18: Mid-Day Market Update: Ascena Retail Tumbles On Weak Guidance; athenahealth Shares Surge

Financial news for ACHN dated on 2017-05-18: Mid-Morning Market Update: Markets Mostly Higher; Wal-Mart Profit Tops Estimates

Financial news for ACHN dated on 2017-05-18: Benzinga's Top Upgrades, Downgrades For May 18, 2017

Financial news for ACHN dated on 2017-05-18: Leerink Swann Upgrades Achillion Pharmaceuticals to Outperform

Financial news for ACHN dated on 2017-05-04: Achillion Reports Q1 EPS \$(0.15) vs \$(0.12) Est.

Financial news for ACHN dated on 2017-04-22: Achillion Announces Study Data Show JNJ-4178 was Highly Effective in Treatment Naive Patients with HCV Genotype 1 Infection without Cirrhosis

Financial news for ACHN dated on 2017-04-19: Option Alert: Achillion Jun 4.0 Calls Sweep: 929 @ ASK \$0.30: 929 traded vs 1101 OI: Earnings 5/2 After Close [est] \$3.67 Ref

Financial news for ACHN dated on 2017-04-06: Achillion Announces Initiation of Patient Dosing in Phase 2 Study of ACH-4471 for Paroxysmal Nocturnal Hemoglobinuria

Financial news for ACHN dated on 2017-03-22: 18 Stocks Moving In Wednesday's Pre-Market Session

Financial news for ACHN dated on 2017-03-21: Achillion Pharma Reports USPTO Has Granted Composition of Matter Patent to Co. for Small Molecule Complement Alternative Pathway Factor D Inhibitors

Financial news for ACHN dated on 2017-02-28: Achillion Pharmaceuticals Announces Support of Natural History Study of C3 Glomerulopathy, a Rare Renal Disorder, Conducted by Experts at Imperial College London

Financial news for ACHN dated on 2017-02-02: The Market In 5 Minutes: Facebook Beats, Trump Tweets

Financial news for ACHN dated on 2017-02-02: Ladenburg On Biotech: Starts Achillion, Alnylam, Corcept, Trevana At Buy

Financial news for ACHN dated on 2017-02-02: Ladenburg Thalmann Initiates Coverage On Achillion Pharmaceuticals at Buy, Announces \$10.00 Target

Financial news for ACHN dated on 2017-01-11: Mid-Afternoon Market Update: Derma Sciences Climbs On Acquisition News; Novadaq Shares Plunge

Financial news for ACHN dated on 2017-01-11: Mid-Day Market Update: Crude Oil Up 2.5%; Ethan Allen Shares Drop On Weak Forecast

Financial news for ACHN dated on 2016-12-28: UPDATE: Achillion Receives \$15M Milestone Payment from J&J's Janssen Research & Development

Financial news for ACHN dated on 2016-12-28: Achillion Reports Clinical Milestone for Advancement of JNJ-4178 in Phase 2B Development for Chronic HPV

Financial news for ACHN dated on 2016-12-19: 18 Stocks Moving In Monday's Pre-Market Session

Financial news for ACHN dated on 2016-12-07: Mid-Morning Market Update: Markets Mostly Lower; Korn/Ferry Beats Q2 Expectations

Financial news for ACHN dated on 2016-11-30: Achillion Says Dosing of Phase 2B Study Initiated by Janssen

Financial news for ACHN dated on 2016-11-29: 10 Stocks With Lowest Close In Three Weeks

Financial news for ACHN dated on 2016-11-23: 10 Stocks With Lowest Close In Three Weeks

Financial news for ACHN dated on 2016-11-04: Chardan Capital Upgrades Achillion Pharmaceuticals, Inc. - Common Stock to Neutral, Announces \$5.00

Financial news for ACHN dated on 2016-11-03: 20 Biggest Mid-Day Losers For Thursday

Financial news for ACHN dated on 2016-11-03: Baird Defending Achillion, Saying That The 30% Selloff In Shares Does Not Make Sense

Financial news for ACHN dated on 2016-11-03: Achillion Pharmaceuticals Reports Q3 Loss/Share \$0.15 vs Est Loss/Share \$0.16

Financial news for ACHN dated on 2016-11-03: Achillion Pharmaceuticals Reports Update On JNJ-4178, Phase I Study Of ACH-4471

Financial news for ACHN dated on 2016-09-26: Chardan Capital Analyst Underscores Achillion Pharma as Sell This Morning, Sees Stock as Overvalued

Financial news for ACHN dated on 2016-09-23: 18 Biggest Mid-Day Gainers For Friday

Financial news for ACHN dated on 2016-09-23: UPDATE: Achillion Says No Clinically Significant Lab, Echocardiography, ECG Abnormalities Were Reported

Financial news for ACHN dated on 2016-09-23: Achillion Reports 100% SVR12 in 6-, 8-Week Cohorts in Janssen's Phase 2 Trial Evaluating Triple Combo Treatment Regimen Showed Sustained Viral Response 12 Weeks After Completion



Financial news for ACHN dated on 2016-09-23: Achillion Shares Halted News Pending

Financial news for ACHN dated on 2016-09-23: 15 Stocks Moving In Friday's Pre-Market Session

Financial news for ACHN dated on 2016-09-22: Wedbush Initiates Coverage on Achillion Pharmaceuticals at Outperform, Announces \$13.00 PT

Financial news for ACHN dated on 2016-09-15: FBR Capital Initiates Coverage on Achillion Pharmaceuticals at Outperform

Financial news for ACHN dated on 2016-09-15: 15 Stocks Moving In Thursday's Pre-Market Session

Financial news for ACHN dated on 2016-09-09: Achillion Pharma Reports 100% SVR Reported in Janssen's Phase 2a Trial Evaluating Triple Combination of Odalasvir, AL-335, and Simeprevir for Genotype 1 Treatment-Naive HCV

Financial news for ACHN dated on 2016-09-07: Watch These 7 Huge Call Purchases In Wednesday Trade

Financial news for ACHN dated on 2016-09-06: Achillion Spikes to High of \$8.40 on Volume

Financial news for ACHN dated on 2016-09-06: Option Alert: ACHN 9/30 7.0 Calls (Wkly) Sweep: 1716 @ ASK \$1.45: 1716 traded vs 40 OI: \$8.15 Ref

Financial news for ACHN dated on 2016-08-04: Achillion Pharmaceuticals Reports Q2 EPS \$(0.14) vs. Est. \$(0.15)

Financial news for ACHN dated on 2016-07-14: Achillion Pharma Initiated At Sell By Chardan, Sees >=60% Downside

Financial news for ACHN dated on 2016-07-14: Benzinga's Top Initiations

Financial news for ACHN dated on 2016-07-14: The Market In 5 Minutes: Bank Of England Keeps Interest Rates On Hold

Financial news for ACHN dated on 2016-07-14: Chardan Capital Initiates Coverage on Achillion Pharmaceuticals at Sell, Announces \$4.00 PT

Financial news for ACHN dated on 2016-07-11: Chardan Analysts Initiate Coverage On Akari Therapeutics With A Sell Rating

Financial news for ACHN dated on 2016-07-07: Achillion Shares Rally Following JMP's Upgrade To Market Outperform

Financial news for ACHN dated on 2016-07-07: Benzinga's Top Upgrades

Financial news for ACHN dated on 2016-07-07: JMP Securities Upgrades Achillion Pharmaceuticals to Market Outperform

Financial news for ACHN dated on 2016-06-10: Achillion Presents Interim Phase 1 Results for ACH-4471 at 21st Congress of the European Hematology Association

Financial news for ACHN dated on 2016-05-19: Achillion Announces Acceptance of Late Breaking Abstract for ACH-4471 at the 21st Congress of the European Hematology Association

Financial news for ACHN dated on 2016-05-03: Achillion Q1 EPS (\$0.13) vs (\$0.14) est, No Revenue

Financial news for ACHN dated on 2016-05-03: Achillion Pharmaceuticals Says by End of 2016 Expects to Report Number of Data Points from Both HCV Program and Ongoing Phase 1 Trial With ACH-4471

Financial news for ACHN dated on 2016-04-22: UPDATE: Achillion Confirms Q1 Earnings Release for Early May

Financial news for ACHN dated on 2016-04-22: UPDATE: Achillion is Participating in Several Conferences in Coming Weeks

Financial news for ACHN dated on 2016-04-22: Achillion Spokesperson Says Never Confirmed for UBS Conference, But Slot Was Assigned for Co

Financial news for ACHN dated on 2016-04-22: Achillion Spikes Higher; Hearing Cancelled Out of UBS Conference

Financial news for ACHN dated on 2016-03-03: Mid-Morning Market Update: Markets Open Lower; Joy Global Reports Wider-Than-Expected Q1 Loss

Financial news for ACHN dated on 2016-02-26: Benzinga's Top Upgrades

Financial news for ACHN dated on 2016-02-26: Baird Upgrades Achillion Pharmaceuticals to Outperform

Financial news for ACHN dated on 2016-02-25: Achillion Pharma Sees FY 2016 EPS \$(0.65)-\$(0.70) Vs Est \$(0.43)

Financial news for ACHN dated on 2016-02-25: Achillion Pharma Reports Q4 EPS \$(0.12) Vs Est \$0.07, Sales \$31.6M Vs Est \$31.59M

Financial news for ACHN dated on 2016-02-16: Point72 Cuts Stake In Achillion Pharma

Financial news for ACHN dated on 2016-01-29: Leerink Swann Downgrades Achillion Pharmaceuticals to Market Perform

Financial news for ACHN dated on 2016-01-28: 7 Biotech Traders Pick Their Favorite Stocks For 2016

Financial news for ACHN dated on 2016-01-04: Achillion Names Dr. Joel Barrish as Chief Scientific Officer

Financial news for ACHN dated on 2015-12-31: Option Alert: ACHN Jun16 14.0 Calls Sweep: 1000 @ ASK \$1.20: 1005 traded vs 63 OI: \$10.74 Ref

Financial news for ACHN dated on 2015-12-31: Najarian Brothers Are Bullish On American Airlines And Achillion Pharma

Financial news for ACHN dated on 2015-12-23: Option Alert: ACHN Mar16 15.0 Calls Sweep: 500 @ ASK \$0.25: 500 traded vs 1010 OI: \$10.08 Ref

Financial news for ACHN dated on 2015-12-07: Achillion Spikes to High; May be Attributed to FT Article on Gilead Seeking Hep C Deal

Financial news for ACHN dated on 2015-12-06: Achillion Announces Upcoming Oral Presentation and Nomination of ACH-4471 at #ASH2015

Financial news for ACHN dated on 2015-11-05: Achillion Pharma Reports Q3 EPS \$0.19 Vs Est \$0.09, Sales \$33.8M Vs Est \$32.69M

Financial news for ACHN dated on 2015-10-22: Achillion Pharma And Express Scripts Both Trading Volatile Following FDA Comments

Financial news for ACHN dated on 2015-10-16: Achillion Announces Janssen Initiated Phase 2a Study to Evaluate Combination of AL-335, ACH-3102, and Simeprevir for Treatment of Genotype 1 Chronic HCV

Financial news for ACHN dated on 2015-09-17: Achillion Issues Press Release Update on SVR12

Financial news for ACHN dated on 2015-09-08: UBS: Biotech Will Continue To Outperform In 2015

Financial news for ACHN dated on 2015-09-08: Morning Market Gainers

Financial news for ACHN dated on 2015-09-08: Benzinga's Top #PreMarket Gainers

Financial news for ACHN dated on 2015-09-08: UBS Upgrades Achillion Pharmaceuticals to Buy

Financial news for ACHN dated on 2015-09-01: Achillion to Present at Baird, Morgan Stanley Conferences

Financial news for ACHN dated on 2015-08-17: Option Alert: Achillion Sep 4 \$8.5 Call Sweep; 1000 Contracts @Ask @\$0.65; Now \$8.73

Financial news for ACHN dated on 2015-08-10: Achillion Pharma Q2 EPS -\$0.25 vs -\$0.18 est, Revenue \$711K

Financial news for ACHN dated on 2015-08-03: Achillion Announces Janssen Initiated Phase I Study to Evaluate Effect of Simeprevir and Odalasvir on AL-335 Pharmacokinetics

Financial news for ACHN dated on 2015-07-07: J&J Reports 15.6% Passive Stake In Achillion Pharmaceuticals as of July 1, 2015

Financial news for ACHN dated on 2015-06-22: Morning Market Losers

Financial news for ACHN dated on 2015-06-22: Benzinga's Top #PreMarket Losers

Financial news for ACHN dated on 2015-05-21: What Does The Johnson & Johnson/Achillion Deal Mean For HCV Competitors?

Financial news for ACHN dated on 2015-05-20: Morning Market Losers

Financial news for ACHN dated on 2015-05-20: Benzinga's Top Downgrades

Financial news for ACHN dated on 2015-05-20: JMP Securities Downgrades Achillion Pharmaceuticals To Market Perform

Financial news for ACHN dated on 2015-05-20: JMP Says Stepping To The Sidelines On Achillion

Financial news for ACHN dated on 2015-05-20: Benzinga's Top #PreMarket Losers

Financial news for ACHN dated on 2015-05-20: UBS Downgrades Achillion Pharmaceuticals to Neutral

Financial news for ACHN dated on 2015-05-20: Achillion Pharmaceuticals Shares Fall ~2% Premarket Following Announcement of Hep C Collaboration With Janssen

Financial news for ACHN dated on 2015-05-20: William Blair Upgrades Achillion Pharmaceuticals to Outperform, Raises PT to \$18.00

Financial news for ACHN dated on 2015-05-20: JMP Securities Downgrades Achillion Pharmaceuticals to Market Perform, Removes \$24.00 PT

Financial news for ACHN dated on 2015-05-19: Shares of Achillion Resume Trade; Now Up 12+% to ~\$11.87

Financial news for ACHN dated on 2015-05-19: Shares of Achillion to Resume Trade at 4:35 p.m. EDT

Financial news for ACHN dated on 2015-05-19: UPDATE: Achillion, Janssen Deal Includes \$225M Investment for ~18.4M Newly Issued, Unregistered Shares of Achillion at \$12.25/Share

Financial news for ACHN dated on 2015-05-19: UPDATE: Achillion, Janssen Collab Includes Up to \$1.1B in Potential Development, Regulatory, Sales Milestone Payments, Separate Equity Investment

Financial news for ACHN dated on 2015-05-19: Achillion Announces Collaboration for Hep C with J&J's Janssen Pharma

Financial news for ACHN dated on 2015-05-19: From Achillion Events Page: Posts Link for Co., Janssen Discussion for HCV Collab Webcast

Financial news for ACHN dated on 2015-05-19: Achillion Shares Halted News Pending

Financial news for ACHN dated on 2015-05-19: Option Alert: Achillion Pharma Jan \$20 Call; 5000 Contract Trade at \$0.95; Now \$10.82

Financial news for ACHN dated on 2015-05-19: Morning Market Losers

Financial news for ACHN dated on 2015-05-19: Benzinga's Top #PreMarket Losers

Financial news for ACHN dated on 2015-05-18: Momo, Take-Two, Urban Outfitters Lead Monday's After-Hours Movers

Financial news for ACHN dated on 2015-05-18: Option Alert: Achillion Pharma Sep 11 Call; 1020 Contract Trade at Ask @\$2.15; Now \$10.99

Financial news for ACHN dated on 2015-05-18: Option Alert: Achillion Pharma Jul \$12 Call; 1113 Contract Trade at Ask @\$0.80

Financial news for ACHN dated on 2015-05-18: Achillion Cancels Presentation At UBS Health Conference

Financial news for ACHN dated on 2015-05-18: Achillion Shares Spike Higher

Financial news for ACHN dated on 2015-05-18: Option Alert: Achillion Pharma Sep 15 Call; 7500 Contract Trade above Ask @\$0.39; Now \$9.65

Financial news for ACHN dated on 2015-05-07: Achillion Q1 EPS -\$0.17 vs -\$0.22 est

Financial news for ACHN dated on 2015-04-25: Achillion Presents Detailed Clinical Results on ACH-3102, ACH-3422 at EASL

Financial news for ACHN dated on 2015-04-24: Achillion Says they Did Not Cancel Out of Presentation

Financial news for ACHN dated on 2015-04-24: Achillion Shares Spike to High on Chatter they have Cancelled a Presentation

Financial news for ACHN dated on 2015-04-09: The Biotech Stocks JMP Is Watching

Financial news for ACHN dated on 2015-03-05: Hearing Leerink Defending Achillion

Financial news for ACHN dated on 2015-03-05: Achillion Q4 EPS -\$0.21 vs -\$0.18, Revenue \$0

Financial news for ACHN dated on 2015-03-04: Barclays Expands Coverage To 7 New Biotech Stocks

Financial news for ACHN dated on 2015-03-04: Barclays Initiates Coverage on Achillion Pharmaceuticals at Underweight, Announces \$8.00 PT

Financial news for ACHN dated on 2015-03-03: After-Hours Movers Led By Bob Evans, Bazaarvoice And Smith & Wesson On Tuesday

Financial news for ACHN dated on 2015-02-24: Option Alert: Achillion Mar \$16 Call; 1800 Contract Trade at Ask @\$0.25; Now \$12.46

Financial news for ACHN dated on 2015-02-17: Top 5 Biotech Stocks That The Smart Money Doesn't Like

Financial news for ACHN dated on 2015-02-12: US Stock Futures Up Ahead Of Jobless Claims, Retail Sales Data

Financial news for ACHN dated on 2015-02-12: Achillion Pharmaceuticals Prices 12M Share Offering @\$10.25/Share

Financial news for ACHN dated on 2015-02-11: Morning Market Losers

Financial news for ACHN dated on 2015-02-11: Benzinga's Top #PreMarket Losers

Financial news for ACHN dated on 2015-02-11: JMP Securities Covers Mostly Good News From Pharma Pending More Visibility

Financial news for ACHN dated on 2015-02-10: Achillion Pharmaceuticals Announces 10M Share Public Offering of Common Stock

Financial news for ACHN dated on 2015-02-09: Gilead's Sofosbuvir Just Made Achillion Investors Very Happy

Financial news for ACHN dated on 2015-02-09: Benzinga's Volume Movers

Financial news for ACHN dated on 2015-02-09: Morning Market Gainers

Financial news for ACHN dated on 2015-02-09: Achillion Pharmaceuticals Shares Surge On Positive Data

Financial news for ACHN dated on 2015-02-09: Monday Morning Movers: Achillion Up, Regulus Down Following Drug Results

Financial news for ACHN dated on 2015-02-09: Benzinga's Top #PreMarket Gainers

Financial news for ACHN dated on 2015-02-09: Adam Feuerstein @adamfeuerstein Tweet: \$ACHN problem: ACH-3422 is not Sovaldi

Financial news for ACHN dated on 2015-02-09: UPDATE: Achillion Shares Rise 8% Premarket on Positive ACH-3102 Data

Financial news for ACHN dated on 2015-02-04: Worst Performing Industries For February 4, 2015

Financial news for ACHN dated on 2015-01-30: What Investors Are Watching For In Regulus Therapeutics' Next Data Release

Financial news for ACHN dated on 2015-01-23: Option Alert: Achillion Jan 30 \$16 Call; 1000 Contract Trade at \$0.63; Now \$16.05

Financial news for ACHN dated on 2015-01-22: Deutsche Bank Loves These Small-Cap Biotech Stocks

Financial news for ACHN dated on 2015-01-12: Wall Street's Hall Of Fame (And Hall Of Shame): The Best And Worst Analyst Recommendations Of 2014

Financial news for ACHN dated on 2015-01-09: Option Alert: Achillion Pharmaceuticals Jan \$16 Call; 2,232 Contract Trade at ask @\$0.25; Currently \$14.12

Financial news for ACHN dated on 2015-01-09: Achillion Shares Move to High on Volume

Financial news for ACHN dated on 2014-12-29: The Top 5 Biotech Gainers Of 2014

Financial news for ACHN dated on 2014-12-29: Morning Market Movers

Financial news for ACHN dated on 2014-12-29: Benzinga's Top #PreMarket Gainers

Financial news for ACHN dated on 2014-12-24: Morning Market Movers

Financial news for ACHN dated on 2014-12-24: Benzinga's Top #PreMarket Gainers

Financial news for ACHN dated on 2014-12-23: Mid-Day Losers From December 23: Achillion Pharmaceuticals, Doral Financial, Keurig Green Mountain And More

Financial news for ACHN dated on 2014-12-23: Worst Performing Industries For December 23, 2014

Financial news for ACHN dated on 2014-12-23: Mid-Morning Market Update: Markets Mostly Higher; Walgreen Profit Beats Expectations

Financial news for ACHN dated on 2014-12-23: Morning Market Losers

Financial news for ACHN dated on 2014-12-23: Tuesday's #PreMarket Movers: NQ Mobile, Cytokinetics, Walgreen And More

Financial news for ACHN dated on 2014-12-23: Benzinga's Top Downgrades

Financial news for ACHN dated on 2014-12-23: Benzinga's Top #PreMarket Losers

Financial news for ACHN dated on 2014-12-23: Baird Downgrades Achillion Pharmaceuticals To Neutral

Financial news for ACHN dated on 2014-12-23: US Stock Futures Edge Higher Ahead Of Economic Data

Financial news for ACHN dated on 2014-12-23: Baird Downgrades Achillion Pharmaceuticals to Neutral, Raises PT to \$16.00

Financial news for ACHN dated on 2014-12-22: Watch Out For These 4 Short Interest Gainers In Monday's Trading

Financial news for ACHN dated on 2014-12-22: Adam Feuerstein @adamfeuerstein Tweet: \$ACHN Takeout Less Likely Following Subpar Hep C Drug Results

Financial news for ACHN dated on 2014-12-22: Benzinga's Volume Movers

Financial news for ACHN dated on 2014-12-22: Stocks Hitting 52-Week Highs

Financial news for ACHN dated on 2014-12-22: Morning Market Movers

Financial news for ACHN dated on 2014-12-22: Achillion Pharmaceuticals Shares Volatile Following Hepatitis C Treatment News

Financial news for ACHN dated on 2014-12-22: Monday's #PreMarket Movers: Caesars, Enta, Twitter And More

Financial news for ACHN dated on 2014-12-22: Benzinga's Top #PreMarket Gainers

Financial news for ACHN dated on 2014-12-22: UPDATE: Achillion Shares Turn Negative

Financial news for ACHN dated on 2014-12-22: US Stock Futures Up Ahead Of Existing-Home Sales Data

Financial news for ACHN dated on 2014-12-22: UPDATE: Achillion Shares Rise 63% Premarket on Positive HCV Treatment Data

Financial news for ACHN dated on 2014-12-22: Achillion Pharmaceuticals Shares Rise 19% Premarket on Positive ACH-3102, ACH-3422 Data

Financial news for ACHN dated on 2014-12-22: Achillion Shows Potential for "Best-in-Disease" HCV Regimen - 100% SVR4 Following a Dual 6-Week ACH-3102-Based Regimen and

Separately a 4.8 Log10 Reduction With ACH-3422

Financial news for ACHN dated on 2014-12-09: Option Alert: Achillion Dec \$15 Call; 1,000 Contract Trade Above Ask @\$1.64; Currently \$14.00

Financial news for ACHN dated on 2014-12-08: These 4 Biotech Stocks Have Been On Fire

Financial news for ACHN dated on 2014-11-19: Option Alert: Achillion Pharmaceuticals Dec \$15 Call; 3,758 Contract Trade at Ask @\$2.30; Currently \$12.91

Financial news for ACHN dated on 2014-11-17: 2 Skyrocketing Biotech Stocks In A Stalling Market

Financial news for ACHN dated on 2014-11-13: Deutsche Bank Mystified By 18% Jump In Achillion Pharmaceuticals

Financial news for ACHN dated on 2014-11-10: Mid-Afternoon Market Update: Sothebys Climbs On Upbeat Revenue; GoPro Shares Dip

Financial news for ACHN dated on 2014-11-10: Mid-Day Market Update: Gogo Shares Slide On Wider Loss; Achillion Pharmaceuticals Shares Jump

Financial news for ACHN dated on 2014-11-10: Mid-Morning Market Update: Markets Edge Higher; Dean Foods Posts Narrower-Than-Expected Loss

Financial news for ACHN dated on 2014-11-10: Achillion Pharma back to High of day on high volume. Co Reported 100% SVR12 in Phase 2 Combo Study

Financial news for ACHN dated on 2014-11-10: Morning Market Movers

Financial news for ACHN dated on 2014-11-10: Benzinga's Top #PreMarket Gainers

Financial news for ACHN dated on 2014-11-08: Achillion Announces 100% SVR12 in Phase 2 Combination Study With ACH-3102 at AASLD Annual Meeting

Financial news for ACHN dated on 2014-11-04: Midday Losers From November 4: Borderfree, Herbalife, Achillion Pharmaceuticals, Discovery Communications

Financial news for ACHN dated on 2014-11-04: Morning Market Losers

Financial news for ACHN dated on 2014-11-04: Achillion Expects to Report Top-Line Results from Ongoing Phase 1 Trial of ACH-3422 Later In Current Quarter; Expects to Initiate Proprietary Combination Program Evaluating ACH3422,ACH-3102,Sovaprevir During 2015

Financial news for ACHN dated on 2014-11-04: Achillion Pharmaceuticals, Inc. Reports Q3 EPS of \$(0.16) vs \$(0.18) Est

Financial news for ACHN dated on 2014-11-03: Option Alert: Achillion Pharmaceuticals Nov 14 \$14 Call; 2,023 Contracts Traded vs 112 OI; Currently \$12.04

Financial news for ACHN dated on 2014-10-08: Achillion Pharmaceuticals, Inc. Shares Trading At Highs Following Positive Comments From FBR Capital

Financial news for ACHN dated on 2014-10-08: Shares of Achillion Pharma at Session Highs as Traders Passing Around Mid-Day Note from FBR Showing Indication from Co. (via Abstract) of '100% of Patients Dosed for Eight Weeks Remained Cured'

Financial news for ACHN dated on 2014-10-08: Hearing Positive FBR Comments on Achillion Pharmaceuticals

Financial news for ACHN dated on 2014-10-08: Achillion Pharmaceuticals to Present Updated Data At AASLD Annual Meeting

Financial news for ACHN dated on 2014-10-07: Shares of Achillion Pharm Edging Into Positive Territory as Hearing UBS Commenting on Bristol-Myers Squibb Look Into Strategic Assets as Boding Well for Co.

Financial news for ACHN dated on 2014-10-06: Top 5 Biotech Stocks Over The Past Year

Financial news for ACHN dated on 2014-10-03: Option Alert: Achillion Pharmaceuticals Nov \$14 Call; 1,144 Contract Trade at Ask @\$1.80; Currently \$10.63

Financial news for ACHN dated on 2014-09-30: Achillion Pharmaceuticals, Inc. Less Attractive Amid Johnson & Johnson/Allos BioPharma Deal

Financial news for ACHN dated on 2014-09-26: Option Alert: Achillion Pharmaceuticals Activity in Oct \$14 Call; Currently \$10.88

Financial news for ACHN dated on 2014-09-25: UPDATE: Achillion Chief Commercial Officer Still Expecting Phase 1 NUC Data by This Fall

Financial news for ACHN dated on 2014-09-25: Achillion CCO Truitt Says NUC Data Will Not Be Late-Breaking Abstract at AASLD

Financial news for ACHN dated on 2014-09-15: Momentum Stocks Showing Weakness

Financial news for ACHN dated on 2014-09-15: Midday Losers From September 15 - Tesla Motors Inc, Digital Ally, Inc. And More

Financial news for ACHN dated on 2014-09-15: Morning Market Losers

Financial news for ACHN dated on 2014-09-15: Option Alert: Achillion Pharmaceuticals Shares Off Lows; Activity in Oct \$14 Call; Currently \$11.07

Financial news for ACHN dated on 2014-09-15: Benzinga's Top #PreMarket Losers

Financial news for ACHN dated on 2014-09-12: Morning Market Losers

Financial news for ACHN dated on 2014-09-12: Benzinga's Top #PreMarket Losers

Financial news for ACHN dated on 2014-09-05: Infoblox Inc Gains On Upbeat Results; The Gap Inc. Shares Decline

Financial news for ACHN dated on 2014-09-05: Markets Edge Lower; Zumiez Issues Weak Outlook

Financial news for ACHN dated on 2014-09-03: Top 5 Performing Biotech Stocks Of 2014

Financial news for ACHN dated on 2014-09-03: Morning Market Movers

Financial news for ACHN dated on 2014-09-03: Benzinga's Top #PreMarket Gainers

Financial news for ACHN dated on 2014-09-02: 13G Filing from RA Capital Mgmt on Achillion Pharma Shows Slightly Reduced Stake from 19% to 18.1%

Financial news for ACHN dated on 2014-09-02: Morning Market Movers

Financial news for ACHN dated on 2014-09-02: Benzinga's Top #PreMarket Gainers

Financial news for ACHN dated on 2014-08-27: Amended 13D Filing from RA Capital Mgmt on Achillion Pharma Shows Reduced 19% Stake

Financial news for ACHN dated on 2014-08-26: Deutsche Bank Sees Achillion, Arrowhead As Potential Takeover Targets

Financial news for ACHN dated on 2014-08-26: Morning Market Movers

Financial news for ACHN dated on 2014-08-26: Benzinga's Top #PreMarket Gainers

Financial news for ACHN dated on 2014-08-25: Benzinga's M&A Chatter for Monday August 25, 2014

Financial news for ACHN dated on 2014-08-25: Achillion Shares Spike Higher, Near \$11 As UBS Analyst Sees Possibility Of M&A

Financial news for ACHN dated on 2014-08-25: UPDATE: Move in Achillion May be Attributed to Positive UBS Analyst Comment

Financial news for ACHN dated on 2014-08-22: Benzinga's Top #PreMarket Losers

Financial news for ACHN dated on 2014-08-20: Amended 13D Filing from RA Capital Mgmt on Achillion Shows Very Slightly Reduced Stake from 22.99% as of Jun. 30th to 21.1%

Financial news for ACHN dated on 2014-08-19: UPDATE: Achillion Has Received US Patent for ACH-3102, Structurally-Related NS5A Inhibitors

Financial news for ACHN dated on 2014-08-19: Achillion Has Received US Patent for ACH-3102

Financial news for ACHN dated on 2014-08-18: Dow Surges 175 Points; Fabrinet Shares Slide

Financial news for ACHN dated on 2014-08-18: Markets Open Higher; Dollar General Offers \$9.7 Billion To Buy Family Dollar

Financial news for ACHN dated on 2014-08-18: Morning Market Movers

Financial news for ACHN dated on 2014-08-18: Deutsche Bank Raises Achillion Price Target 183%

Financial news for ACHN dated on 2014-08-18: Benzinga's Top #PreMarket Gainers

Financial news for ACHN dated on 2014-08-18: Deutsche Bank Upgrades Achillion Pharmaceuticals, Inc. to Buy, Raises PT to \$17.00

Financial news for ACHN dated on 2014-08-15: Markets Close The Week On Negative Note As Ukraine Worries Mount

Financial news for ACHN dated on 2014-08-15: U.S. Stocks Turn Lower; Dillard's Shares Slide On Downbeat Earnings

Financial news for ACHN dated on 2014-08-15: Markets Gain; J.C. Penney Posts Narrower-Than-Expected Q2 Loss

Financial news for ACHN dated on 2014-08-15: Stocks Hitting 52-Week Highs

Financial news for ACHN dated on 2014-08-15: Morning Market Movers

Financial news for ACHN dated on 2014-08-15: Benzinga's Top #PreMarket Gainers

Financial news for ACHN dated on 2014-08-15: Achillion Achieves 100% Sustained Virologic Response Rate from 8-Week Phase 2 Trial Evaluating Ribavirin-Free Regimen of ACH-3102 and Sofosbuvir for Genotype 1 HCV

Financial news for ACHN dated on 2014-08-11: Morning Market Movers

Financial news for ACHN dated on 2014-08-11: Benzinga's Top Upgrades

Financial news for ACHN dated on 2014-08-11: Piper Jaffray Upgrades Achillion Pharmaceuticals To Overweight

Financial news for ACHN dated on 2014-08-11: Benzinga's Top #PreMarket Gainers

Financial news for ACHN dated on 2014-08-11: Wells Fargo Upgrades Achillion Pharmaceuticals, Inc. to Outperform

Financial news for ACHN dated on 2014-08-11: Piper Jaffray Upgrades Achillion Pharmaceuticals, Inc. to Overweight, Raises PT to \$10.00

Financial news for ACHN dated on 2014-08-08: JMP Securities Upgrades Achillion Pharmaceuticals, Inc. to Market Outperform, Maintains \$13.00 PT

Financial news for ACHN dated on 2014-08-01: Achillion Pharmaceuticals Shares Move Higher on Unconfirmed Market Chatter of Potential Bid from Bristol-Myers Squibb

Financial news for ACHN dated on 2014-07-03: Exclusive: Enanta Pharmaceuticals CEO Jay Luly Discusses Hep C Pipeline

Financial news for ACHN dated on 2014-06-27: Exclusive: Hepatitis C Stock Valuation With Enanta CEO Jay Luly

Financial news for ACHN dated on 2014-06-20: Baird Comments On Achillion's Bullish Share Action

Financial news for ACHN dated on 2014-06-19: From Press Release: Nearly Three-Quarters of Surveyed Primary Care Physicians are Unfamiliar with Approved Direct Acting Antivirals for Hepatitis C Virus

Financial news for ACHN dated on 2014-06-19: Achillion Pharmaceuticals Spikes Higher

Financial news for ACHN dated on 2014-06-18: Benzinga's Top #PreMarket Losers

Financial news for ACHN dated on 2014-06-17: Benzinga's Top #PreMarket Losers

Financial news for ACHN dated on 2014-06-16: Mid-Day Market Movers For Monday, June 16, 2014

Financial news for ACHN dated on 2014-06-16: Mid-Morning Market Update: Markets Mostly Higher; Medtronic To Acquire Covidien For \$42.9B

Financial news for ACHN dated on 2014-06-16: Morning Market Movers

Financial news for ACHN dated on 2014-06-16: Maxim Group Significantly Raises Achillion's PT, Shares Soar +15%

Financial news for ACHN dated on 2014-06-13: Mid-Afternoon Market Update: Markets



Reverse Early Loses; Oil Continues To Rise On Overseas Worry

Financial news for ACHN dated on 2014-06-13: Mid-Morning Market Update: Markets Mostly Flat; Priceline To Acquire OpenTable For \$103/Share

Financial news for ACHN dated on 2014-06-13: Morning Market Losers

Financial news for ACHN dated on 2014-06-13: Benzinga's Top #PreMarket Losers

Financial news for ACHN dated on 2014-06-11: Achillion Pharmaceuticals Director Kishbauch Sells 371,937 Shares @\$7.75/Share -Form 4

Financial news for ACHN dated on 2014-06-11: Takeover Whispers Add To Achillion Pharmaceuticals' Momentum

Financial news for ACHN dated on 2014-06-11: UBS Upgrades Achillion Pharmaceuticals, Inc. to Buy

Financial news for ACHN dated on 2014-06-11: Benzinga's Top Upgrades

Financial news for ACHN dated on 2014-06-11: Baird Upgrades Achillion Pharmaceuticals, Inc. to Outperform, Raises PT to \$12.00

Financial news for ACHN dated on 2014-06-10: Mid-Afternoon Market Update; RadioShack Misses More Than Expected, BE Aerospace To Split Into Two Companies

Financial news for ACHN dated on 2014-06-10: Mid-Day Market Update: Francesca's Falls On Downbeat Results; Achillion Shares Jump

Financial news for ACHN dated on 2014-06-10: Mid-Morning Market Update: Markets Open Lower; RadioShack Reports Wider Loss

Financial news for ACHN dated on 2014-06-10: Morning Market Movers

Financial news for ACHN dated on 2014-06-10: Benzinga's Top #PreMarket Gainers

Financial news for ACHN dated on 2014-06-10: JMP Securities Upgrades Achillion Pharmaceuticals, Inc. to Market Outperform, Announces \$13.00 PT

Financial news for ACHN dated on 2014-06-10: UPDATE: Achillion Pharmaceuticals Shares Rise 37% Premarket, Following 47% Rise on Monday, After Reporting Initiation of ACH-3422 Dosing in HCV-Infected Patients

Financial news for ACHN dated on 2014-06-10: Achillion Initiates ACH-3422 Dosing in HCV-Infected Patients

Financial news for ACHN dated on 2014-06-09: Top Healthcare Movers For June 9, 2014

Financial news for ACHN dated on 2014-06-09: Hearing Leering Says JNJ, AbbVie, Bristol-Myers Squibb Could Target Achillion Pharmaceuticals

Financial news for ACHN dated on 2014-06-09: Morning Market Movers

Financial news for ACHN dated on 2014-06-09: Hepatitis C Stocks Move After Idenix Rockets Up 235%

Financial news for ACHN dated on 2014-06-09: Benzinga's Top #PreMarket Gainers

Financial news for ACHN dated on 2014-06-09: Achillion Pharmaceuticals Shares Rise 38% Premarket on News of Merck-Idenix Deal

Financial news for ACHN dated on 2014-05-07: Achillion Pharmaceuticals Reports Q1 EPS of \$(0.17) vs \$(0.16) Est

Financial news for ACHN dated on 2014-04-30: Achillion Advances ACH-3422 Into Clinical Trial, Initiates Phase 2 Pilot Study With ACH-3102

Financial news for ACHN dated on 2014-03-24: Maxim Group Upgrades Achillion Pharmaceuticals, Inc. to Buy

Financial news for ACHN dated on 2014-03-14: Morning Gainers for Friday, March 14, 2014

Financial news for ACHN dated on 2014-03-14: Benzinga's Top #PreMarket Gainers

Financial news for ACHN dated on 2014-03-14: Achillion Announces Positive Results in Phase 2 Trial of ACH-3102, Second-Generation NS5A Inhibitor, Against Genotype 1b HCV

Financial news for ACHN dated on 2014-03-07: Achillion Pharma Files Shelf Offering

for Up to \$150M

Financial news for ACHN dated on 2014-03-07: Achillion Pharmaceuticals, Inc. Sees FY2014 EPS \$(0.70) vs \$(0.79) Est

Financial news for ACHN dated on 2014-03-07: Achillion Pharmaceuticals Reports Q4 EPS of \$(0.14) vs \$(0.16) Est; Revenue of \$0.00 vs \$10.0K Est

Financial news for ACHN dated on 2014-01-13: Achillion Reports HCV Pipeline Progress and Outlines 2014 HCV Milestones

Financial news for ACHN dated on 2013-12-02: Benzinga's Top #PreMarket Gainers

Financial news for ACHN dated on 2013-11-04: Benzinga's Top #PreMarket Gainers

Financial news for ACHN dated on 2013-11-02: Achillion's ACH-3422 Shows Compelling Preclinical Profile

Financial news for ACHN dated on 2013-10-16: Credit Suisse Downgrades Achillion Pharmaceuticals, Inc. to Neutral

Financial news for ACHN dated on 2013-10-15: Achillion Pharmaceuticals Spikes Higher on Volume

Financial news for ACHN dated on 2013-09-30: Deutsche Bank Downgrades Achillion Pharmaceuticals, Inc. to Hold, Lowers PT to \$4.00

Financial news for ACHN dated on 2013-09-30: Wells Fargo Downgrades Achillion Pharmaceuticals, Inc. to Market Perform

Financial news for ACHN dated on 2013-09-30: UPDATE: Piper Jaffray Downgrades Achillion Pharmaceuticals as Pipeline Setback Pushes Out Approval

Financial news for ACHN dated on 2013-09-30: Morning Market Losers

Financial news for ACHN dated on 2013-09-30: Piper Jaffray Downgrades Achillion Pharmaceuticals, Inc. to Neutral, Lowers PT to \$5.00

Financial news for ACHN dated on 2013-09-30: UPDATE: Bank of America Downgrades Achillion Pharmaceuticals Following Extremely Negative Pipeline Update

Financial news for ACHN dated on 2013-09-30: William Blair Downgrades Achillion Pharmaceuticals, Inc. to Market Perform, Lowers PT to \$5.00

Financial news for ACHN dated on 2013-09-30: JMP Securities Downgrades Achillion Pharmaceuticals, Inc. to Market Perform, Removes \$12.00 PT

Financial news for ACHN dated on 2013-09-30: Benzinga's Top Downgrades

Financial news for ACHN dated on 2013-09-30: UPDATE: Achillion Shares Fall 51% Pre-Market on Friday's Clinical Hold Announcement

Financial news for ACHN dated on 2013-09-30: Bank of America Downgrades Achillion Pharmaceuticals, Inc. to Underperform, Lowers PO to \$2.00

Financial news for ACHN dated on 2013-09-27: Achillion Shares Fall 43% on Clinical Hold Update

Financial news for ACHN dated on 2013-09-27: Achillion Pharma Shares to Resume Trade at 5PM EDT

Financial news for ACHN dated on 2013-09-27: Achillion Pharma Announces Unable to Resolve Clinical Hold

Financial news for ACHN dated on 2013-09-27: Shares of Achillion Halted News Pending

Financial news for ACHN dated on 2013-08-22: These Three Speculative Small Caps Are Loved By Insiders and Institutions

Financial news for ACHN dated on 2013-08-07: Achillion Pharmaceuticals, Inc. Reports Q2 EPS of \$(0.21) vs \$(0.15) Est

Financial news for ACHN dated on 2013-07-02: Market Wrap for Tuesday, July 2: Stocks Close Near Unchanged Mark in Quiet Session

Financial news for ACHN dated on 2013-07-02: Mid-Afternoon Market Update: Markets Turn Back; Noodles & Company Continues to Rally

Financial news for ACHN dated on 2013-07-02: Afternoon Market Losers for July 2, 2013

Financial news for ACHN dated on 2013-07-02: Afternoon Market Losers

Financial news for ACHN dated on 2013-07-02: Mid-Day Market Update: Acuity Surges On Upbeat Results, Linn Energy Falls

Financial news for ACHN dated on 2013-07-02: Achillion Analysts Weigh In; Maxim Downgrades, Highlights HCV Drug's Need for Extreme Levels of Safety

Financial news for ACHN dated on 2013-07-02: Benzinga's Top Pre-Market Losers

Financial news for ACHN dated on 2013-07-02: Maxim Group Downgrades Achillion Pharmaceuticals to Hold

Financial news for ACHN dated on 2013-07-02: Benzinga Market Primer: Tuesday, July 2: Futures Gain Into Fed Speak

Financial news for ACHN dated on 2013-07-01: UPDATE: A. Schulman Shares Now Down ~14%; Achillion Shares Bounced Now Down ~15%

Financial news for ACHN dated on 2013-07-01: Shares of Achillion Pharma Resume Trade, Now Down 20%

Financial news for ACHN dated on 2013-07-01: Achillion Pharma Shares to Resume Trade at 4:35PM EDT

Financial news for ACHN dated on 2013-07-01: Achillion Says FDA Issues Hold on Sovarprevir Study, Says Ongoing Enrollment-Treatment Unaffected in Phase 2

Financial news for ACHN dated on 2013-07-01: Achillion Halted News Pending

Financial news for ACHN dated on 2013-05-31: Option Alert: Achillion Pharmaceuticals January 10/20 Call Spread; 10,000 @\$1.30; Currently \$8.30

Financial news for ACHN dated on 2013-05-30: Achillion Announces Nomination of ACH-3422 as Nucleotide for Treatment of Chronic HCV

Financial news for ACHN dated on 2013-05-28: Achillion Names Milind Deshpande, Ph.D., as President, Chief Executive Officer, Following Announced Retirement of Michael Kishbauch

Financial news for ACHN dated on 2013-05-15: Achillion Names Dr. David Apelian CMO

Financial news for ACHN dated on 2013-05-07: Achillion Pharmaceuticals, Inc. Reports Q1 EPS of \$(0.14) vs \$(0.15) Est

Financial news for ACHN dated on 2013-04-30: Achillion Pharmaceuticals Spikes Higher

Financial news for ACHN dated on 2013-04-23: Deutsche Bank's Young Called Achillion Data from This Morning 'Very Impressive,' Sees 'Significant Upside, Important Derisking' for Co. Ahead of Results from Combo Study

Financial news for ACHN dated on 2013-04-23: Achillion Announces Updated Phase 2 Results for ACH-3102 Plus Ribavirin in Genotype 1b Treatment-Naive Hepatitis C Patients

Financial news for ACHN dated on 2013-03-04: UPDATE: Piper Jaffray Cuts PT to \$15 on Achillion Pharmaceuticals on Equity Offering Dilution

Financial news for ACHN dated on 2013-03-04: Piper Jaffray Maintains Overweight on Achillion Pharmaceuticals, Inc., Lowers PT to \$15.00

Financial news for ACHN dated on 2013-02-27: Achillion Pharma Closes Offering of 16.89M at \$8.40/Share for Net Proceeds \$133.5M

Financial news for ACHN dated on 2013-02-21: Achillion Pharmaceuticals Prices 15M Share Offering at \$8.40/Share

Financial news for ACHN dated on 2013-02-21: Noble Financial Downgrades Achillion Pharmaceuticals, Inc. to Hold, Maintains \$18.00 PT

Financial news for ACHN dated on 2013-02-20: Achillion Pharmaceuticals, Inc. Reports Q4 EPS of \$(0.14) vs \$(0.20) Est; Revenue of \$118.0K, Up 90% YOY

Financial news for ACHN dated on 2013-02-20: Achillion Pharma Announces \$125M Common Stock Offering

Financial news for ACHN dated on 2013-01-07: Mid-Afternoon Market Update: Markets Down Slightly, Molycorp Rises

Financial news for ACHN dated on 2013-01-07: Mid-Day Market Update: SolarCity Wins Big, SunPower Continues its Fall

Financial news for ACHN dated on 2013-01-07: Morning Market Losers

Financial news for ACHN dated on 2013-01-07: Achillion Pharmaceuticals Announces Interim Results on Phase 2a Trial of ACH-3102

Financial news for ACHN dated on 2013-01-03: Baird Initiates Coverage on Achillion Pharmaceuticals, Inc. at Outperform, Announces \$17.00 PT

Financial news for ACHN dated on 2012-12-26: Bank of America Merrill Lynch Reiterates Buy Rating, \$13 PT on Achillion Pharmaceuticals

Financial news for ACHN dated on 2012-11-13: UBS Maintains Achillion Pharmaceuticals at Neutral, Raises PT from \$6 to \$8

Financial news for ACHN dated on 2012-11-12: Mid-Afternoon Market Update: Markets Near Flat; J.C. Penney Falling Further

Financial news for ACHN dated on 2012-11-12: Mid-Day Market Update: Markets Slow Their Rally; JC Penney Spikes Lower

Financial news for ACHN dated on 2012-11-12: Achillion Provides Update on Clinical HCV Development Programs, Announces New Phase 1b Clinical Trial

Financial news for ACHN dated on 2012-11-08: Achillion Pharmaceuticals Reports Q3 EPS \$-0.20 vs \$-0.17 Est; Revenues \$0.00 vs \$50.00K Est

Financial news for ACHN dated on 2012-10-16: Deutsche Bank Maintains Achillion Pharmaceuticals at Buy, Raises PT from \$12 to \$17

Financial news for ACHN dated on 2012-10-12: Achillion Pharmaceuticals Spikes Higher

Financial news for ACHN dated on 2012-09-27: Benzinga's Top Pre-Market Gainers

Financial news for ACHN dated on 2012-09-27: Achillion Announces Positive Proof-of-Concept Data With ACH-3102

Financial news for ACHN dated on 2012-09-19: UPDATE: Deutsche Bank Initiates Coverage on Achillion Pharmaceuticals with Buy Rating, \$12 PT

Financial news for ACHN dated on 2012-09-19: Morning Market Movers

Financial news for ACHN dated on 2012-09-19: Achillion Pharmaceuticals Rises 13.5% Pre-Market on Deutsche Bank Initiation, Bank of America Upgrade

Financial news for ACHN dated on 2012-09-19: UPDATE: Deutsche Bank Initiates Buy on Achillion Pharmaceuticals

Financial news for ACHN dated on 2012-09-19: Benzinga's Top Pre-Market Gainers

Financial news for ACHN dated on 2012-09-19: UPDATE: Bank of America Upgrades Achillion Pharmaceuticals to Buy on Pipeline Outlook

Financial news for ACHN dated on 2012-09-19: Bank of America Upgrades Achillion Pharmaceuticals from Underperform to Buy, Raises PO from \$7 to \$13

Financial news for ACHN dated on 2012-09-19: Deutsche Bank Initiates Coverage on Achillion Pharmaceuticals at Buy, Announces PT of \$12

Financial news for ACHN dated on 2012-09-13: Achillion Pharmaceuticals Spiking Higher

Financial news for ACHN dated on 2012-09-11: Achillion Pharmaceuticals Spiking Higher

Financial news for ACHN dated on 2012-08-31: UPDATE: Piper Jaffray Reiterates Overweight Rating, Lowers PT on Achillion Pharmaceuticals

Financial news for ACHN dated on 2012-08-31: Piper Jaffray Maintains Achillion Pharmaceuticals at Overweight, Lowers PT from \$17 to \$16

Financial news for ACHN dated on 2012-08-30: Achillion to Raise \$41.8 Million Through Registered Direct Offering

Financial news for ACHN dated on 2012-08-27: Option Alert: Achillion Pharmaceuticals September 7.5 Call; Block Trade: 3,000 Contracts @\$0.35; Currently \$6.78

Financial news for ACHN dated on 2012-08-22: Benzinga's M&A Chatter for Wednesday

August 22, 2012

Financial news for ACHN dated on 2012-08-22: Achillion Spokesperson Not Commenting on Cowen Note Citing Possible Buyout

Financial news for ACHN dated on 2012-08-22: Cowen and Company Maintains Achillion Pharmaceuticals at Outperform

Financial news for ACHN dated on 2012-08-22: Achillion Spikes Higher on Cowen Note Citing Possible Buyout

Financial news for ACHN dated on 2012-08-16: Benzinga's Top Upgrades

Financial news for ACHN dated on 2012-08-09: Bank of America Maintains Achillion Pharmaceuticals at Underperform, Lowers PO from \$10 to \$7

Financial news for ACHN dated on 2012-08-08: Achillion Pharmaceuticals Reports Q2 EPS \$-0.16 vs \$-0.17 Est

Financial news for ACHN dated on 2012-06-29: Hearing Positive Chatter in Achillion Pharmaceuticals

Financial news for ACHN dated on 2012-06-06: Achillion Announces Resignation of Chief Medical Officer

Financial news for ACHN dated on 2012-05-15: A Peek Into The Market Before The Trading Starts

Financial news for ACHN dated on 2012-05-15: ACH-3102 Receives Fast Track Designation From the FDA for the Treatment of Chronic Hepatitis C

Financial news for ACHN dated on 2012-05-07: UPDATE: UBS Investment Research Upgrades Achillion to Neutral; Balanced Risk/Reward

Financial news for ACHN dated on 2012-05-07: UBS Upgrades Achillion Pharmaceuticals from Sell to Neutral, Lowers PT from \$7 to \$6

Financial news for ACHN dated on 2012-04-23: Hearing Baird Positive on Achillion Pharmaceuticals

Financial news for ACHN dated on 2012-04-23: Achillion Clarifies End of Treatment Data From Phase 2a Trial With ACH-1625 Based Regimen in Hepatitis C

Financial news for ACHN dated on 2012-04-23: Benzinga's Top Pre-Market Losers

Financial news for ACHN dated on 2012-04-23: Benzinga's Top Downgrades

Financial news for ACHN dated on 2012-04-23: Hearing JMP Securities Downgrades Achillion Pharmaceuticals from Outperform to Market Perform

Financial news for ACHN dated on 2012-04-21: Achillion Announces 94 - 100% Complete EVR From Phase 2 Trial With ACH-1625 Based Regimen in Hepatitis C

Financial news for ACHN dated on 2012-04-19: Hearing JP Morgan Making Positive Comments on Achillion Pharmaceuticals; Saying it Could Be Takeover Candidate. Saying Buy on Weakness

Financial news for ACHN dated on 2012-04-19: Notable Options Activity in Achillion Pharmaceuticals, Inc.

Financial news for ACHN dated on 2012-04-19: Hearing Wells Fargo Making Positive Comments, Defending Achillion Pharmaceuticals

Financial news for ACHN dated on 2012-04-19: Benzinga's Top Pre-Market Losers

Financial news for ACHN dated on 2012-04-12: UBS Initiates Coverage on Achillion Pharmaceuticals at Neutral, Announces PT of \$11

Financial news for ACHN dated on 2012-03-08: UPDATE: Bank of America Raises Actuant's PT

Financial news for ACHN dated on 2012-03-08: Piper Jaffray: Achillion Pharmaceuticals Ended 2011 with \$80M Cash

Financial news for ACHN dated on 2012-03-08: Hearing Piper Jaffray Positive on Achillion Pharmaceuticals

Financial news for ACHN dated on 2012-02-27: Later Today, Citi Global Health Care Conference, Achillion Pharma and Idenix Pharma Presenting

Financial news for ACHN dated on 2012-02-23: Achillion Pharmaceuticals Spokesperson Says No News Related to Price Move; Will Be Presenting at Citi Healthcare Conference on Monday

Financial news for ACHN dated on 2012-02-23: Achillion Pharmaceuticals Spiking Higher

Financial news for ACHN dated on 2012-02-17: Gilead Falls On Disappointing Hep C Drug Data; Analysts Remain Bullish

Financial news for ACHN dated on 2012-02-17: Gilead Sciences Negative Data Ripples through Biotech Field, Boosting Vertex, Achillion; Knocking Idenix

Financial news for ACHN dated on 2012-02-17: Achillion Pharmaceuticals Spiking Higher on Gilead Hep C Data

Financial news for ACHN dated on 2012-02-16: Achillion Pharmaceuticals Announces Virology Profile Following Treatment With ACH-1625 Discussed in Oral Presentation at 2012 Asian Pacific Liver Conference

Financial news for ACHN dated on 2012-02-14: Achillion CEO Says in Talks That Are in Best Interest of Holders -Bloomberg

Financial news for ACHN dated on 2012-02-08: Benzinga's M&A Chatter for Wednesday February 8, 2012

Financial news for ACHN dated on 2012-02-07: Benzinga's Top Pre-Market Losers

Financial news for ACHN dated on 2012-02-07: Financial Breakfast: Morning News Summary for February 07, 2012

Financial news for ACHN dated on 2012-02-07: UPDATE: Bank of America Downgrades Achillion Pharmaceuticals to Underperform

Financial news for ACHN dated on 2012-02-07: Bank of America Downgrades Achillion Pharmaceuticals from Buy to Underperform, Lowers PO from \$11 to \$10

Financial news for ACHN dated on 2012-02-02: Benzinga's M&A Chatter for Thursday February 2, 2012

Financial news for ACHN dated on 2012-02-02: Achillion Pharmaceuticals Trading 6.5% Higher on Heavy Volume; Currently at \$11.81

Financial news for ACHN dated on 2012-02-02: Achillion Pharmaceuticals Spokesperson Would Not Comment on Rumor of Vertex Offer

Financial news for ACHN dated on 2012-02-02: Hearing Achillion Pharmaceuticals Accepted \$19.75 Offer From Vertex, Not Confirmed

Financial news for ACHN dated on 2012-02-02: Positive Rumors Circulate About Achillion Pharmaceuticals

Financial news for ACHN dated on 2012-01-24: Benzinga's M&A Chatter for Tuesday January 24, 2012

Financial news for ACHN dated on 2012-01-24: Afternoon Movers; Negative Euro News

Financial news for ACHN dated on 2012-01-24: Achillion Pharmaceuticals Spiking Higher on Renewed Takeover Chatter

Financial news for ACHN dated on 2012-01-20: Benzinga's M&A Chatter for Friday January 20, 2012

Financial news for ACHN dated on 2012-01-20: End-of-Day Market Summary for January 20, 2012

Financial news for ACHN dated on 2012-01-20: Afternoon Movers; Markets Moved Sideways

Financial news for ACHN dated on 2012-01-19: Negative Article by Seeking Alpha on Achillion

Financial news for ACHN dated on 2012-01-19: Achillion's Hep C Pipeline Likely Can't Compete

Financial news for ACHN dated on 2012-01-18: Achillion Pharmaceuticals Spiking Lower on Heavy Volume

Financial news for ACHN dated on 2012-01-18: Notable Call Options Activity in Achillion Pharmaceuticals

Financial news for ACHN dated on 2012-01-13: Achillion Pharmaceuticals Trading 9.2% Higher on Heavy Volume; Currently at \$12.84

Financial news for ACHN dated on 2012-01-13: Achillion Pharmaceuticals Hits 52-Week High of \$12.52

Financial news for ACHN dated on 2012-01-13: Achillion Pharmaceuticals Trading 2.8% Higher on Heavy Volume; Currently at \$12.09

Financial news for ACHN dated on 2012-01-11: Achillion Pharmaceuticals Hits 52-Week High of \$12.25

Financial news for ACHN dated on 2012-01-10: Achillion Pharmaceuticals Spokesperson Attributes Today's 22% Price Rise to Monday's PR on Protease Inhibitors Related to Treatment of Hep-C

Financial news for ACHN dated on 2012-01-10: End-of-Day Market Summary for January 10, 2012

Financial news for ACHN dated on 2012-01-10: Afternoon Movers; Markets Moved Higher

Financial news for ACHN dated on 2012-01-10: Achillion Pharmaceuticals Trading 21.2% Higher on Heavy Volume; Currently at \$11.78

Financial news for ACHN dated on 2012-01-10: Achillion Pharma and Idenix Pharma Both Seeing Strength as Companies Present at JPM Health Conference, Likely Attributed to Potential Takeover Targets

Financial news for ACHN dated on 2012-01-10: Going Nuclear on Hepatitis C -- Is Idenix the Next Target?

Financial news for ACHN dated on 2012-01-10: Achillion Pharmaceuticals Trading 6.5% Higher on Heavy Volume; Currently at \$10.35

Financial news for ACHN dated on 2012-01-10: Achillion Pharmaceuticals Spiking Higher on Heavy Volume; Currently at \$10.35

Financial news for ACHN dated on 2012-01-09: Afternoon Movers; Markets Moved Higher

Financial news for ACHN dated on 2012-01-09: Just What The Doctor Ordered: 4 ETFs For Biotech M&A

Financial news for ACHN dated on 2012-01-09: Forget Dendreon, Inhibitex is the New Biotech Success Story

Financial news for ACHN dated on 2012-01-09: Achillion Reports Clinical Data on Portfolio of Protease Inhibitors

Financial news for ACHN dated on 2012-01-04: ACH-1625 Receives Fast Track Designation From the FDA for the Treatment of Chronic Hepatitis C

Financial news for ACHN dated on 2011-12-27: Best Biotech Stocks of 2011

Financial news for ACHN dated on 2011-12-12: Investor Ideas' Biotech/ Pharma Stocks To Watch: Friday's Gainers

Financial news for ACHN dated on 2011-12-05: Achillion Announces Preliminary Phase 1b Proof-of-Concept Data With ACH-2928 NS5A Inhibitor for the Treatment of Hepatitis C

Financial news for ACHN dated on 2011-12-05: Idenix Pharmaceuticals An Intriguing Market Mover Worth Watching

Financial news for ACHN dated on 2011-11-29: Speculative Rumors Continue Circulating About Achillion Pharmaceuticals

Financial news for ACHN dated on 2011-11-29: Achillion Pharmaceuticals Spokesperson Confirms Company Cancelled Out of Wednesday's Piper Conference Due to Scheduling Conflict

Financial news for ACHN dated on 2011-11-29: Achillion Pharmaceuticals Spiking Higher; May be Attributed to Company Cancelling Out of Piper Conference Wednesday

Financial news for ACHN dated on 2011-11-29: UPDATE: Wells Fargo Initiates Coverage on Achillion Pharmaceuticals

Financial news for ACHN dated on 2011-11-29: Wells Fargo Initiates Coverage on Achillion Pharma at Outperform

Financial news for ACHN dated on 2011-11-28: Notable Put Options Activity in Achillion Pharmaceuticals

Financial news for ACHN dated on 2011-11-22: Piper Jaffray Reiterates Overweight Rating on Achillion Pharmaceuticals

Financial news for ACHN dated on 2011-11-21: Hep-C Stocks Soar On M&A News

Financial news for ACHN dated on 2011-11-21: GILD Acquires VRUS

Financial news for ACHN dated on 2011-11-18: Achillion Pharmaceuticals Spokesperson Says Company Policy to Seek Partnering and Strategic Options; Nothing Imminent at this Time

Financial news for ACHN dated on 2011-11-18: Achillion's CEO Says Company in Talks with Potential Buyers

Financial news for ACHN dated on 2011-11-18: Achillion Pharmaceuticals Spiking Higher on Heavy Volume

Financial news for ACHN dated on 2011-11-07: Piper Jaffray Maintains Overweight Rating and \$12 PT on Achillion Pharmaceuticals

Financial news for ACHN dated on 2011-10-17: Biotech Leads Friday's NASDAQ Winners

Financial news for ACHN dated on 2011-10-14: Achillion Pharma Spiking Higher on Heavy Volume

Financial news for ACHN dated on 2011-10-13: Achillion Announces Nomination of Second Generation NS5A Inhibitor for the Treatment of Hepatitis C

Financial news for ACHN dated on 2011-09-08: Thursday's Top Percentage Gainers and Losers

Financial news for ACHN dated on 2011-09-08: Hearing Chatter that Achillion CEO is Open to Acquisition by Pharmasset

Financial news for ACHN dated on 2011-07-11: Bank Of America Updates Achillion Pharmaceuticals Model

Financial news for ACHN dated on 2011-07-11: A Peek Into The Market Before The Trading Starts

Financial news for ACHN dated on 2011-07-11: Achillion Announces Initiation of Phase 1 Trial of ACH-2928 for the Treatment of Hepatitis C

Financial news for ACHN dated on 2011-07-08: Top Performing Small Cap Stocks: July 7th (APAC, OCZ, BEBE, ACHN, HOTT)

Financial news for ACHN dated on 2011-07-08: Top Performing Small Cap Stocks: July 7th (APAC, OCZ, BEBE, ACHN, HOTT)

Financial news for ACHN dated on 2011-06-29: Stocks to Watch for 6/29/11: Fresh 52 Week Highs and Lows

Financial news for ACHN dated on 2011-06-28: Top Percentage Gainers and Losers as of 2pm 6/28/11

Financial news for ACHN dated on 2011-06-28: Achillion Pharmaceuticals Spiking Higher After DealReporter Story

Financial news for ACHN dated on 2011-06-28: 8 Chart-Busting Trade Setups for Today

Financial news for ACHN dated on 2011-06-22: Achillion Initiates 12-Week Dosing in Phase 2 Trial of ACH-1625 for the Treatment of Chronic Hepatitis C

Financial news for ACHN dated on 2011-06-22: Achillion Pharmaceuticals Trading Over 11% Higher After Pricing 9.6M Share Offering at \$5.90

Financial news for ACHN dated on 2011-06-22: Benzinga's Top Pre-Market NASDAQ Gainers

Financial news for ACHN dated on 2011-06-22: Achillion Pharmaceuticals Announces Pricing Offering for 9.6M Shares of Common Stock at \$5.90/Share

Financial news for ACHN dated on 2011-06-21: Top Percentage Gainers and Losers as of 2pm 6/21/11

Financial news for ACHN dated on 2011-06-20: Achillion Pharmaceuticals Down Over 4% After Announcing 9M Share Offering



Financial news for ACHN dated on 2011-06-20: Achillion Pharmaceuticals Announces Proposed Public Offering of Common Stock; An Additional 9M Shares

Financial news for ACHN dated on 2011-06-17: Brean Murray Initiates Achillion Pharmaceuticals At Buy, \$9 PT

Financial news for ACHN dated on 2011-05-25: Achillion Announces Initiation of Phase 1 Trial of ACH-2684 for the Treatment of Hepatitis C

Financial news for ACHN dated on 2011-05-09: Top Percentage Gainers and Losers as of 2pm 5/09/11 (FFLL, ROSE, ONTY, DTG, HTZ, SYU, SCEI, SMI, CERS, HW, ZRAN, MOBI, OXGN, GKK, LFT, HRB, ACHN)

Financial news for ACHN dated on 2011-05-06: Top Percentage Gainers and Losers as of 2pm 5/06/11 (OXGN, LXU, PRO, ACHN, ELON, SAPE, ALJ, JOBS, GSIT, SCEI, IGOI, ARAY, NTSP, ZINC, ZOLT, TPC)

Financial news for ACHN dated on 2011-03-30: Options Brief: Achillion Pharmaceuticals. (ACHN)

Financial news for ACHN dated on 2011-03-30: Achillion Pharmaceuticals Trading Higher Pre-Market (ACHN)

Financial news for ACHN dated on 2011-03-30: Achillion Announces Positive RVR Results With ACH-1625 to Treat Chronic Hepatitis C

Financial news for ACHN dated on 2011-03-22: Hot Stock Movers to watch on Wednesday

Financial news for ACHN dated on 2011-03-03: Oppenheimer Comments On 4Q10 Results For Achillion Pharmaceuticals

Financial news for ACHN dated on 2010-08-19: Benzinga's Top Pre-Market NASDAQ Losers (BRCD, ACHN, CRUS, NTAP)

Financial news for ACHN dated on 2010-05-12: Early Volume Plays Among Those Valued Below \$10 (ACHN, SMTX, CWS, STV)

Financial news for ACHN dated on 2010-05-12: Benzinga's Top Pre-Market Gainers (SMTX, NLST, ACHN, AEZS, VICL)

Financial news for ACHN dated on 2010-01-22: Benzinga's Top Pre-Market Losers (ACHN, DEAR, SYNA, FCEL, GOOG, IBKR)

Financial news for ACHN dated on 2009-12-24: Benzinga's Top Pre- Market Gainers (NCTY, QCOR, DRYS, ACHN, RINO, AMZN)

Financial news for ACHN dated on 2009-12-23: Benzinga's Top Gainers (CGEN, THC, FSII, ACHN, VG)

Financial news for ACHN dated on 2009-12-23: Benzinga's Top Pre- Market Gainers (TIBX, PSDV, ACHN, FINL, SNDK, BLDP)

Financial news for ACHN dated on 2009-12-16: Benzinga's Top Gainers (DPTR, ACHN, CZZ, ING, FBP, TWTC)

Financial news for ACHN dated on 2009-12-16: NASDAQ Pre-market: Top Advanced (ACHN, FGXI, GIGM, ARRY, JOYG)

Financial news for ACHN dated on 2009-12-16: Benzinga's Top Pre- Market Gainers (SOLF, ACHN, FGXI, GIGM, ARRY, SCHW)